2. Anti-infection
  3. SARS-CoV
  4. Lenzilumab

Lenzilumab  (Synonyms: KB 003)

Cat. No.: HY-P99207 Purity: 99.64%
COA
SDS
Technical Support

Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.

For research use only. We do not sell to patients.

CAS No. : 1229575-09-0

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Lenzilumab Featured Recommendations:

Lenzilumab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Lenzilumab

Others

    Lenzilumab purchased from MedChemExpress. Usage Cited in: Arthritis Res Ther. 2025 Sep 26;27(1):180.  [Abstract]

    Extracellular acidification rate (ECAR) measured by Seahorse assay in HMDMs exposed to RA serum with or without IL-1RN, infliximab, or lenzilumab (10 µg/mL).

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2].

    Isotype

    Human IgG1(K214R) kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    CSF2/GM-CSF
    In Vivo

    Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NSG mice with CART19 cells[1]
    Dosage: 10 mg/kg
    Administration: Intraperitoneal injection; daily; 10 days
    Result: Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI).
    Clinical Trial
    Gene ID

    1437  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    145.72 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Lenzilumab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Loaded Lenzilumab on AHC2 biosensor, can bind GM-CSF Protein, Human (His, HY-P7016C) with an affinity constant of 5.364E-10 M as determined in BLI assay.
    • Lenzilumab(HY-P99207) neutralizes Recombinant Human GM-CSF (HY-P7016A) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.02545μg/mL in the presence of 0.5 ng/mL Recombinant Human GM-CSF.
    Purity & Documentation

    Purity: 99.64%

    SDS (251 KB)

    COA (232 KB) SDS-PAGE (83 KB) SEC-HPLC (118 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Lenzilumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Lenzilumab1229575-09-0KB 003KB003KB-003SARS-CoVSARS coronavirusCSF2GM-CSFmonoclonal antibodyCOVID-19leukemiaCMMLJMMLInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Lenzilumab
    Cat. No.:
    HY-P99207
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.